Josh Hardy, age 7, will be allowed to die because a drug company executive doesn’t want to provide the drug he needs.
Update: 10.15.14: CBS News:
Seven-year-old cancer survivor Josh Hardy began receiving an experimental drug Wednesday that his family had been pleading for as a potential last hope, doctors at St. Jude Children’s Hospital in Memphis told reporters Thursday.
St. Jude’s CEO Dr. William Evans said the boy tolerated the drug well to date, but still needed “intensive medical support and attention.”
Since taking the drug, he’s looked “relatively good” and even wanted to go outside.
Josh’s story got national attention this week when his plight exploded on social and news media.
Update: 10/11/14: Josh Hardy will be given the drug on Wednesday.
“This 20-patient open-label study underscores Chimerix’s mission to develop innovative antiviral therapies in areas of high unmet need — for everyone,” Kenneth Moch, the CEO for Chimetrix said. “Being unable to fulfill requests for compassionate use is excruciating, and not a decision any one of us ever wants to have to make. It is essential that each individual in a health crisis be treated with equal gravity and value, a principle we have upheld by pursuing further clinical study of brincidofovir that will inform its use in adenovirus and other serious DNA viral infections.”
Original Story: If a little boy asked his father if he was going to die, and if he died, who would take care of him in heaven, would you give him a drug that could save his life? Under our healthcare system, a drug company is so powerful that it can refuse to give a drug to save a child’s life and the reason can be that they won’t engage in class warfare and save only one child.
Chimerix, is refusing to provide the drug – Brincidofovir – to a dying little boy, even though it could save his life after he fought so hard against cancer.
Josh Hardy, age 7, survived four bouts of kidney cancer, heart failure, and a bone marrow transplant. The treatments led to his getting a deadly virus but he can be cured with a drug that a drug company will not give him.
Kenneth Moch, the CEO of the drug company, Chimerix, said they cannot make an exception because it’s a question of ethics and class warfare. If he gives it to this one little boy, he has to give it to everyone. Moch hung up on the vice Chair of the charity trying to save little Josh’s life.
There is one last appeal available that is being made to the Board of Directors of Chimerix.
The drug is not yet FDA-approved but it has been given to hundreds of people in trials. [A report today said he is the first person to be part of the trial. The Sentinel can’t determine the truth.]
At first, Moch said that the company couldn’t afford it so a charity – MaxCare – came up with the money. Then he said he can’t do it for ethical reasons and the charity is engaging in class warfare.
This is the same attitude that Kathleen Sebelius had when she declined to save the life of the little girl, Sarah Murnahan, who needed a lung transplant to save her life. It is our new healthcare system philosophy. We no longer give to the needy. We give to all or none or it’s called class warfare. As Sebelius said with a shrug, “Someone lives, someone dies.”
Josh has been cancer-free for two years but in order for the bone marrow to work, doctors had to suppress his immune system which led to his catching the adenovirus that will kill him by the weekend without the drug.
This drug company has received $72 million from the federal government – that is our tax money – and they will not turn the drug over.
The company is receiving hundreds of calls in support of Josh. Please call or tweet or email or do all three to help save this little boy’s life.
To help save Josh, Hardy is encouraging supporters to call Chimerix at 919-806-1074; supporters can also e-mail firstname.lastname@example.org or tweet @chimerix using the hashtag #savejosh.
Listen to the details from Richard Plotkin Vice Chair of the Marx-Care Foundation and the child’s mother, Aimee Hardy: